ARTICLE | Company News
Kamada withdraws MAA for inhaled AAT
June 22, 2017 11:21 PM UTC
Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said that following discussions with EMA, it withdrew its MAA for inhaled alpha-1 antitrypsin (AAT; A1AT; SERPINA1) to treat AAT deficiency. The company said it does not believe existing data would be sufficient to support approval, and that an additional trial would be required.
On Thursday, the company lost NIS627 (23%) to NIS2,048 in Tel Aviv and sank $1.20 (16%) to $6.30 on NASDAQ. The company announced the news before NASDAQ market hours and during Tel Aviv market hours. ...
BCIQ Company Profiles
BCIQ Target Profiles